News Releases

DSMB Has Reviewed Interim Clinical and Safety Data and Recommended that the Study Continue SAN DIEGO , June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose,

New Director Named with Significant Executive Management and Financial Leadership Experience SAN DIEGO , May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of

David J. Marguglio , Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo , Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO , May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and

SAN DIEGO , May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and

High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC ( US WorldMeds ), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S.

SAN DIEGO , March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor

Tempol Reduced Lung Inflammation After High Dose Challenge SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston,

SAN DIEGO , March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level.

DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that on March 11, 2022 , the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3

SAN DIEGO , March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams , effective April 15, 2022 . “Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided

Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo

SAN DIEGO , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,

SAN DIEGO , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now

SAN DIEGO , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.

Drug overdoses are the leading cause of death for those under age 50 SAN DIEGO , Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is

SAN DIEGO , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and

SAN DIEGO , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference

New High-Dose Naloxone Product for the Treatment of Opioid Overdose SAN DIEGO , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL

Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization SAN DIEGO , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the appointment of Meera J. Desai , Ph.D., as a new director and member of

SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.

SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto , who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr.

Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly. SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer